Home / Resource Library / 4-YEAR UPDATE OF PHASE 2 ELARA TRIAL: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

4-YEAR UPDATE OF PHASE 2 ELARA TRIAL: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

EHA 2025

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

4-YEAR UPDATE OF PHASE 2 ELARA TRIAL: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)